US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

10.85

-1.0200-8.59%

Post-market: 10.850.00000.00%16:12 EDT

Volume:67.76K

Turnover:745.75K

Market Cap:528.79M

PE:0.00

High:12.00

Open:12.00

Low:10.51

Close:11.87

52wk High:17.45

52wk Low:10.50

Shares:48.74M

Float Shares:12.50M

Volume Ratio:0.34

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3,391.5288

EPS(LYR):-2,395.7345

ROE:--

ROA:--

PB:-3.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041

Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement

Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel

Agomab Therapeutics NV Director Felice Isabel Verduyn-van Weegen Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV Director Angelika Martha Jahreis Files Initial Beneficial Ownership Statement

Agomab Therapeutics Nv : Van Lanschot Kempen Initiates Coverage With Buy Rating; Price Target $33

THOMSON REUTERS

Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)

AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from Leerink Partners

JPMorgan Initiates AgomAb Therapeutics at Overweight

MT Newswires Live

Morgan Stanley Initiates AgomAb Therapeutics at Overweight

MT Newswires Live

Leerink Initiates AgomAb Therapeutics at Outperform With $36 Price Target

MT Newswires Live

Agomab Therapeutics Nv : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $36

THOMSON REUTERS

AgomAb Therapeutics Initiated at Overweight by Morgan Stanley

Agomab Therapeutics Nv : JP Morgan Initiates Coverage With Overweight Rating; Target Price $32

THOMSON REUTERS

Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO

European Equities Traded in the US as American Depositary Receipts Higher Wednesday

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AGMB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":10.85,"timestamp":1774641600000,"preClose":11.87,"halted":0,"volume":67757,"hourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.85,"latestTime":"16:12 EDT","volume":10,"amount":108.4,"timestamp":1774642337817,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.08593091828138161,"floatShares":12500000,"shares":48736779,"eps":-3391.5288,"marketStatus":"Market Closed","change":-1.02,"latestTime":"03-27 16:00:00 EDT","open":12,"high":12,"low":10.51,"amount":745754.2202,"amplitude":0.125527,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3391.5288,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.87,"postHourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.85,"latestTime":"16:12 EDT","volume":10,"amount":108.4,"timestamp":1774642337817,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3392113890043081},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":12500000,"roa":"--","roe":"--","lyrEps":-2395.734548,"volumeRatio":0.3392113890043081,"shares":48736779,"dividePrice":0,"high":12,"amplitude":0.125527,"preClose":11.87,"low":10.51,"week52Low":10.5,"pbRate":"-3.00","week52High":17.4528,"institutionHeld":0,"latestPrice":10.85,"eps":-3391.5288,"divideRate":0,"volume":67757,"delay":0,"ttmEps":-3391.5288,"open":12,"prevYearClose":16,"prevWeekClose":12.19,"prevMonthClose":16.02,"prevQuarterClose":16,"fiveDayClose":12.19,"twentyDayClose":16.02,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1773892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-03-27","current":-0.003199,"percent":0.970588,"low":-14.725744,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"high":-10.600815,"avg":-13.107825,"sd":1.105762,"marketCap":578505566},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566}],"updateTime":1774761603526},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622085155","title":"Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2622085155","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622085155?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:01","pubTimestamp":1774522892,"startTime":"0","endTime":"0","summary":"Agomab said the USPTO granted U.S. Patent No. 12,577,230 covering the composition of matter of AGMB-447.AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5  in a Phase 1b study for idiopathic pulmonary fibrosis.The company said the patent provides U.S. IP protection through at least 2041, excluding potential patent term extensions.CEO Tim Knotnerus said Agomab expects results from the idiopathic pulmonary fibrosis patient cohort of the Phase 1b study later this year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2yYlHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","NDAQ","AGMB","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","BK4112","SG9999014039.USD","BK4007","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2622212859","title":"Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622212859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622212859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA6BRHW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2622851262","title":"Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851262?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262841/0/en/Agomab-Receives-U-S-Patent-for-AGMB-447-its-Inhaled-Lung-restricted-Small-Molecule-Inhibitor-of-ALK5-in-Development-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IP","AGMB","LU1481600234.SGD","LU1169590202.USD","LU2463526074.USD","BK4136","LU1169589451.USD","LU1481599808.USD","BK4588","BK4585","LU1487256676.USD","IE00B3T34201.USD","BK4007"],"gpt_icon":0},{"id":"2620473264","title":"Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473264","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620473264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:03","pubTimestamp":1773864192,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director David Epstein. Epstein disclosed stock options to buy 770,671 common shares at an exercise price of USD 2.81. He also reported stock options to buy 217,295 common shares at an exercise price of USD 5.26. In addition, Epstein reported stock options to buy 38,843 common shares at an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2nntt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"gpt_icon":0},{"id":"2620644382","title":"Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620644382","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620644382?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:03","pubTimestamp":1773864183,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership by Tim Jasper Knotnerus, a director and chief executive officer. The filing listed 10,823 common shares held directly by Knotnerus. It also reported 34,394 common shares held indirectly through TJK Life Sciences. The filing disclosed stock options covering 683,248 common shares with an exercise price of USD 0.0005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbllKNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"gpt_icon":0},{"id":"2620264410","title":"Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264410","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264410?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864177,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership by director Ohad Hammer. The filing listed a stock option for 27,921 common shares. The option has an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL98LGY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"gpt_icon":0},{"id":"2620126441","title":"Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel","url":"https://stock-news.laohu8.com/highlight/detail?id=2620126441","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620126441?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864168,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel. Agomab Therapeutics reported an initial statement of beneficial ownership by Philippe Constantin Wiesel, its chief medical officer. The filing listed stock options covering 21,732 common shares with an exercise price of USD 1.13. It also listed stock options covering 155,433 common shares with an exercise price of USD 0.0005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7l047W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2620726445","title":"Agomab Therapeutics NV Director Felice Isabel Verduyn-van Weegen Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620726445","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620726445?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864154,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director Felice Isabel Verduyn-van Weegen. The filing listed a stock option to buy 32,700 common shares. The option had an exercise price of USD 14.26. The option expiration date was Jan. 15, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbglz9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2620264460","title":"Agomab Therapeutics NV Director Angelika Martha Jahreis Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264460","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264460?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864149,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director Angelika Jahreis. The filing listed stock options covering 94,438 common shares with an exercise price of USD 3.1. It also reported stock options for 31,505 common shares with an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4WJWZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2620125813","title":"Agomab Therapeutics Nv : Van Lanschot Kempen Initiates Coverage With Buy Rating; Price Target $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2620125813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620125813?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:53","pubTimestamp":1773834818,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN40613U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2618992931","title":"Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618992931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618992931?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:36","pubTimestamp":1773139003,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on AgomAb Therapeutics NV ADR, with a price target of $28...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGMB"],"gpt_icon":0},{"id":"2617391543","title":"AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2617391543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617391543?lang=en_us&edition=fundamental","pubTime":"2026-03-05 18:05","pubTimestamp":1772705132,"startTime":"0","endTime":"0","summary":"In a report released on March 3, Thomas Smith from Leerink Partners initiated coverage with a Buy rating on AgomAb Therapeutics NV ADR and a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"gpt_icon":0},{"id":"2616474543","title":"JPMorgan Initiates AgomAb Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2616474543","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616474543?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:34","pubTimestamp":1772541270,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates AgomAb Therapeutics at Overweight","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"gpt_icon":0},{"id":"2616347923","title":"Morgan Stanley Initiates AgomAb Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347923","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347923?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541037,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates AgomAb Therapeutics at Overweight","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"gpt_icon":0},{"id":"2616347940","title":"Leerink Initiates AgomAb Therapeutics at Outperform With $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347940?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541030,"startTime":"0","endTime":"0","summary":"Leerink Initiates AgomAb Therapeutics at Outperform With $36 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"gpt_icon":0},{"id":"2616441653","title":"Agomab Therapeutics Nv : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2616441653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616441653?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:55","pubTimestamp":1772538949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2616346639","title":"AgomAb Therapeutics Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2616346639","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616346639?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:35","pubTimestamp":1772534100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 05:35 ET (10:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"gpt_icon":0},{"id":"2616450390","title":"Agomab Therapeutics Nv : JP Morgan Initiates Coverage With Overweight Rating; Target Price $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2616450390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616450390?lang=en_us&edition=fundamental","pubTime":"2026-03-03 13:20","pubTimestamp":1772515224,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"gpt_icon":0},{"id":"2613894397","title":"Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2613894397","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613894397?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:54","pubTimestamp":1771847658,"startTime":"0","endTime":"0","summary":"UPDATE 3-Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPOAdds analyst comment in paragraphs 3,6,7By Arasu Kannagi BasilFeb 23 (Reuters) - Drug developer Generate Biomedicine","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4N3ZJ0P5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","EIKN","LU0320765646.SGD","MANE","MRNX","IE00B2B36J28.USD","BK4127","LU0158827781.USD","BK4551","LU1989772923.USD","LU2750360641.GBP","LU2089284900.SGD","LU0158827948.USD","LU1732800096.USD","LU2471134879.HKD","IE00BZ1G4Q59.USD","IE0009355771.USD","LU0225283273.USD","LU0528227936.USD","BK4566","LU0795875086.SGD","LU2242646821.SGD","LU1548497426.USD","MRNA","LU0345770308.USD","GSX","IE00BSNM7G36.USD","PIPR","BK4548","LU1668664300.SGD","LU0251142724.SGD","LU1868836914.USD","LU2112291526.USD","BK4148","AMGN","LU2028103732.USD","LU1244550494.USD","MRNY","BK4568","LU2471134523.USD","LU0795875169.SGD","LU1791710582.SGD","AGMB","SGP","LU0106261372.USD","BK4534","LU0048573561.USD","LU2265009873.SGD","SG9999001440.SGD","AKTS"],"gpt_icon":0},{"id":"2612702442","title":"European Equities Traded in the US as American Depositary Receipts Higher Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2612702442","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612702442?lang=en_us&edition=fundamental","pubTime":"2026-02-19 00:15","pubTimestamp":1771431312,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Wednesday morning, up 1.28% to 1,858.13 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by energy company Equinor  and semiconductor firm ASML , which rose 3.4% and 3.3% respectively. They were followed by clinical-stage biotech company Abivax  and bank Banco Santander , which added 2.9% and 2.5%, respectively.The decliners from continental Europe were led by clinical-stage biopharmaceutical company Agomab Therapeutics  and online shopping company LuxExperience , which fell 5.4% and 5.2%, respectively. They were followed by healthcare company Fresenius , which was down 2.6%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways  and software development firm Endava , which gained 9.8% and 3.7% respectively.The decliners from the UK and Ireland were led by clinical diagnostic products provider Trinity Biotech  and pharmaceutical company Sil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LUXE","BK4134","BK4139","LU0345774391.USD","TRIB","SAN","CMPS","LU0823434740.USD","BK4207","BK4521","AGMB","LU0648005311.SGD","LU2063271972.USD","BK4117","BK4196","BK4585","ABVX","IE0004445239.USD","LU0084288595.USD","BK4094","BK4082","BK4201","LU1734074674.USD","ASML","IE00BD6J9T35.USD","03165","EQNR","BK4147","LU0823434583.USD","BK4543","SLN","BK7142","BK7129","LU0345774631.USD","FMS","LU0097036916.USD","DAVA","BK4588","BK4107"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}